NasdaqCM - Nasdaq Real Time Price USD

ImmuCell Corporation (ICCC)

5.05 +0.01 (+0.20%)
As of 11:53 AM EDT. Market Open.
Loading Chart for ICCC
DELL
  • Previous Close 5.04
  • Open 5.13
  • Bid --
  • Ask --
  • Day's Range 5.04 - 5.13
  • 52 Week Range 4.26 - 6.05
  • Volume 4,491
  • Avg. Volume 7,269
  • Market Cap (intraday) 39.142M
  • Beta (5Y Monthly) 0.60
  • PE Ratio (TTM) --
  • EPS (TTM) -0.75
  • Earnings Date May 9, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

immucell.com

74

Full Time Employees

December 31

Fiscal Year Ends

Recent News: ICCC

Performance Overview: ICCC

Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

ICCC
0.79%
S&P 500
5.10%

1-Year Return

ICCC
2.43%
S&P 500
21.17%

3-Year Return

ICCC
52.58%
S&P 500
19.92%

5-Year Return

ICCC
16.53%
S&P 500
71.25%

Compare To: ICCC

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: ICCC

Valuation Measures

Annual
As of 4/25/2024
  • Market Cap

    39.06M

  • Enterprise Value

    54.78M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.23

  • Price/Book (mrq)

    1.56

  • Enterprise Value/Revenue

    3.14

  • Enterprise Value/EBITDA

    -21.25

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -33.05%

  • Return on Assets (ttm)

    -7.36%

  • Return on Equity (ttm)

    -20.86%

  • Revenue (ttm)

    17.47M

  • Net Income Avi to Common (ttm)

    -5.77M

  • Diluted EPS (ttm)

    -0.75

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    978.74k

  • Total Debt/Equity (mrq)

    66.78%

  • Levered Free Cash Flow (ttm)

    -4.51M

Research Analysis: ICCC

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Earnings

Consensus EPS
 

Company Insights: ICCC

Fair Value

5.05 Current
 

Dividend Score

0 Low
ICCC
Sector Avg.
100 High
 

Hiring Score

0 Low
ICCC
Sector Avg.
100 High
 

Insider Sentiment Score

0 Low
ICCC
Sector Avg.
100 High
 

People Also Watch